Cilag Acquires Exclusive Worldwide Rights of Argenx’s Cusatuzumab (ARGX-110) for $1.6B

 Cilag Acquires Exclusive Worldwide Rights of Argenx’s Cusatuzumab (ARGX-110) for $1.6B

Cilag Acquires Exclusive Worldwide Rights of Argenx’s Cusatuzumab (ARGX-110) for $1.6B

Shots:

  • Cilag (subsidiary of Janssen) to get worldwide commercialization rights for Cusatuzumab, with an option for Argenx to take part in the US activities. Argenx to receive $300M upfront, $200M equity investment and up to $1.3M as milestone plus tiered royalties(ex- US) on sales
  • The companies have agreed to share profit equally in the US and plans to evaluate cusatuzumab in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
  • Cusatuzumab is an anti-CD70 Ab, currently evaluated with Vidaza (Azacitidine) in P-I/II & P-II trial for AML & high-risk MDS and r/r cutaneous T-cell lymphoma (CTCL) respectively

Click here to read full press release/ article | Ref: Argenx | Image: Argenx

 

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post